pondocillin powder for oral suspension 175 mg/5ml
leo laboratories limited - pivampicillin - powder for oral suspension - 175 mg/5ml
talpen tablets 250 milligram
smithkline beecham pharm ltd - talampicillin - tablets - 250 milligram
talpen syrup 125 milligram
smithkline beecham pharm ltd - talampicillin - syrup - 125 milligram
talpen 125 milligram
smithkline beecham pharm ltd - talampicillin - 125 milligram
talpen 125 mg/5 ml
smithkline beecham pharm ltd - talampicillin - syrup - 60 millilitre
talpen 125 mg/5 ml
smithkline beecham pharm ltd - talampicillin - syrup - 100 millilitre
actonorm gel
wallace manufacturing chemists limited - dimethicone, activated, aluminium hydroxide, magnesium hydroxide - oral suspension - dimethicone, activated 25 milligram(s) ; aluminium hydroxide 220 milligram(s) ; magnesium hydroxide 200 milligram(s) - drugs for functional gastrointestinal disorders
epilim liquid sodium valproate 40 mg/ml sugar free oral liquid bottle
sanofi-aventis australia pty ltd - sodium valproate, quantity: 40 mg/ml - oral liquid - excipient ingredients: purified water; sorbitol solution (70 per cent) (non-crystallising); sodium methyl hydroxybenzoate; citric acid; brilliant scarlet 4r; hyetellose; sodium propyl hydroxybenzoate; saccharin sodium; flavour - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate
epilim sodium valproate 100mg crushable tablet blister pack
sanofi-aventis australia pty ltd - sodium valproate, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; silicon dioxide; kaolin; maize starch - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate
epilim syrup
sanofi-aventis australia pty ltd - sodium valproate, quantity: 40 mg/ml - oral liquid - excipient ingredients: sorbitol; sodium propyl hydroxybenzoate; sodium methyl hydroxybenzoate; saccharin sodium; brilliant scarlet 4r; purified water; sucrose; flavour - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate